CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 109, Issue 2, 2000, Pages 173-180

  Karandikar, Nitin J ^a   Eagar, Todd N ^a   Vanderlugt, Carol L ^a   Bluestone, Jeffrey A ^b   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Autoimmunity; Costimulation; CTLA 4; EAE; Epitope Spreading

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; MONOCLONAL ANTIBODY; MYELIN;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE COURSE; ENCEPHALOMYELITIS; FEMALE; IMMUNOREACTIVITY; IMMUNOREGULATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ACUTE DISEASE; AMINO ACID SEQUENCE; ANIMAL; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION; AUTOANTIGENS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, EXPERIMENTAL AUTOIMMUNE; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN BASIC PROTEINS; PHOSPHOLIPIDS; RECURRENCE; REMISSION, SPONTANEOUS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES;

EID: 0034703310     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00322-2     Document Type: Article

References (28)

1. Allison J.P., Chambers C., Hurwitz A., Sullivan T., Boitel B., Fournier S., Brunner M., Krummel M. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found. Symp. 215:1998;92-98.
2. Begolka W.S., Vanderlugt C.L., Rahbe S.M., Miller S.D. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. 161:1998;4437-4446.
3. Chambers C.A., Krummel M.F., Boitel B., Hurwitz A., Sullivan T.J., Fournier S., Cassell D., Brunner M., Allison J.P. The role of CTLA-4 in the regulation and initiation of T cell responses. Immunol. Rev. 153:1996;27-46.
4. Gribben J.G., Freeman G.J., Boussiotis V.A., Rennert P., Jellis C.L., Greenfield E., Barber M., Resvito V.A., Ke X., Gray G.S., Nadler L.M. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA. 92:1995;811-815.
5. Hurwitz A.A., Sullivan T.J., Krummel M.F., Sobel R.A., Allison J.P. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J. Neuroimmunol. 73:1997;57-62.
6. June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. The B7 and CD28 receptor families. Immunol. Today. 15:1994;321-331.
7. Karandikar N.J., Vanderlugt C.L., Bluestone J.A., Miller S.D. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J. Neuroimmunol. 89:1998;10-18.
8. Karandikar N.J., Vanderlugt C.L., Eagar T., Tan L., Bluestone J.A., Miller S.D. Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis. J. Immunol. 161:1998;192-199.
9. Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., Bluestone J.A. CTLA-4: A negative regulator of autoimmune disease. J. Exp. Med. 184:1996;783-788.
10. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155:1995;1032-1036.
11. Kennedy M.K., Torrance D.S., Picha K.S., Mohler K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:1992;2496-2505.
12. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:1995;459-465.
13. Krummel M.F., Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:1996;2533-2540.
14. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1996;1734-1736.
15. Lehmann P.V., Sercarz E.E., Forsthuber T., Dayan C.M., Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol. Today. 14:1993;203-208.
16. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:1996;233-258.
17. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174:1991;561-569.
18. Luhder F., Hoeglund P., Allison J.P., Benoist C., Mathis D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187:1998;427-432.
19. McRae B.L., Kennedy M.K., Tan L.J., Dal Canto M.C., Miller S.D. Induction of active and adoptive chronic-relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 38:1992;229-240.
20. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182:1995;75-85.
21. Miller S.D., Vanderlugt C.L., Lenschow D.J., Pope J.G., Karandikar N.J., Dal Canto M.C., Bluestone J.A. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity. 3:1995;739-745.
22. Perkins D., Wang Z., Donovan C., He H., Mark D., Guan G., Wang Y., Walunas, Bluestone J., Listman J. Regulation of CTLA-4 expression during T cell activation. J. Immunol. 156:1996;4154-4159.
23. Perrin P.J., Maldonado J.H., Davis T.A., June C.H., Racke M.K. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157:1996;1333-1336.
24. Suvannavejh G.C., Dal Canto M.C., Matis L.A., Miller S.D. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 105:2000;223-231.
25. Vanderlugt C.L., Eagar T.N., Neville K.L., Nikcevich K.M., Bluestone J.A., Miller S.D. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J. Immunol. 164:2000;670-678.
26. Vanderlugt C.L., Miller S.D. Epitope spreading. Curr. Opin. Immunol. 8:1996;831-836.
27. Walunas T.L., Bakker C.Y., Bluestone J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183:1996;2541-2550.
28. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., Thompson C.B., Bluestone J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:1994;405-413.